Trials / Unknown
UnknownNCT03083054
Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
Cellular Immunotherapy as a Treatment Option for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- University of Campinas, Brazil · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this work is to conduct a clinical study for the development and application of a vaccine with autologous dendritic cells submitted to electroporation with Wilm's tumor 1 (WT1) messenger ribonucleic acid (mRNA), as an adjuvant treatment of high-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia, aiming to delay the progression of the disease or its relapse and increase overall and event-free survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Autologous dendritic cells electroporated with WT1 mRNA | Production and application of autologous dendritic cells vaccines, 4 doses, biweekly |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2020-07-12
- Completion
- 2021-07-01
- First posted
- 2017-03-17
- Last updated
- 2020-10-12
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT03083054. Inclusion in this directory is not an endorsement.